Author

Fiona Elwood

Observed name: Elwood, Fiona

Institution: Johnson & Johnson (United States)

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Johnson & Johnson (United States), Stanford Medicine, Pharmaron (China), Stanford University

ORCID: 0000-0002-4354-920X

Observed ORCID: 0000-0002-4354-920X

OpenAlex ID: A5037295229

Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease

2020 · Simon Dujardin, Caitlin Commins, et al. · Nature Medicine · 434

Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival

2013 · Jian Luo, Fiona Elwood, et al. · The Journal of Experimental Medicine · 261

A proteogenomic view of Parkinson’s disease causality and heterogeneity

2023 · Sergio Kaiser, Luqing Zhang, et al. · npj Parkinson s Disease · 64

Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties

2025 · Nilufer P. Seth, Rui Xu, et al. · mAbs · 37

Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor

2017 · Fiona Elwood, David J. Witter, et al. · Journal of Pharmacology and Experimental Therapeutics · 32

Genome-wide CRISPR screen identifies protein pathways modulating tau protein levels in neurons

2021 · Carlos G. Sanchez, Christopher M. Acker, et al. · Communications Biology · 30

Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors

2016 · Vladimir Simov, Sujal V. Deshmukh, et al. · Bioorganic & Medicinal Chemistry Letters · 25

Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force

2024 · D. Angioni, J. Cummings, et al. · The Journal of Prevention of Alzheimer s Disease · 22

The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties

2017 · Tony Siu, Jason Brubaker, et al. · Journal of Medicinal Chemistry · 19

Krabbe Disease: Prospects of Finding a Cure Using AAV Gene Therapy

2021 · Gibran Nasir, Rajiv Chopra, et al. · Frontiers in Medicine · 13

Vesicle trafficking and pathways to neurodegeneration

2021 · Craig Blackstone, Fiona Elwood, et al. · Molecular Neurodegeneration · 11

Author Correction: Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease

2021 · Simon Dujardin, Caitlin Commins, et al. · Nature Medicine · 8

High-throughput screen of 100 000 small molecules in C9ORF72 ALS neurons identifies spliceosome modulators that mobilize G4C2 repeat RNA into nuclear export and repeat associated non-canonical translation

2025 · Maartje J Luteijn, Varun Bhaskar, et al. · Nucleic Acids Research · 7

Tau biology, biomarkers, and therapeutics

2025 · Bess Frost, Hartmuth Kolb, et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 4

The evolution of Alzheimer’s target identification: Towards a fusion of artificial and cellular intelligence

2025 · Gayle Wittenberg, Fiona Elwood, et al. · The Journal of Prevention of Alzheimer s Disease

Works count: 17

Citation count: 966

H-index: 11

I10-index: 11